Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
NCT03661320Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2018
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of nivolumab in muscle-invasive bladder cancer (MIBC), sponsored by Bristol Myers Squibb. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03661320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03661320.